Rosemary Mazanet, M.D., PhD. Joins Columbia Care's Board of Directors
11 Settembre 2023 - 2:05PM
Business Wire
Columbia Care Inc. (NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP)
(“Columbia Care” or the “Company”), one of the largest and most
experienced cultivators, manufacturers and retailers of cannabis
products in the U.S., today announced the transition of Rosemary
Mazanet, M.D., PhD., from Chief Scientific Officer, a role she has
held since 2017, to a member of the Company’s Board of Directors,
effective immediately.
Dr. Mazanet began advising Columbia Care in 2013 and then joined
its Scientific Advisory Board as its Chair in 2015. Since 2013, she
has played an integral role of developing groundbreaking form
factors specifically for palliative care, such as pressed tablets.
She also oversaw the creation of the seminal cannabis observational
database that has provided analysis used in peer-reviewed journals,
such as JAMA and the Journal of Palliative Medicine and by many of
the nation’s leading academic and medical institutions such as
National Institutes of Health, Columbia University, New York
University, Mount Sinai, University of Southern California, and
RAND Corporation. This database has also been used by policymakers
at the federal and state level contributing to the development of
cannabis policies that have advanced the industry. Following review
and consideration, Dr. Mazanet was recommended for appointment by
the Company’s Nominating and Governance Committee given her ability
to contribute and add value to the Board based of her extensive
medical, scientific, Company, industry, and public company
experience.
"The consumers and communities we serve are always at the heart
of what we do. Rosemary has been a leading voice and organizational
leader as Columbia Care developed and evolved, while at the same
time, serving as a pillar to ensure we maintained fidelity to our
mission of improving peoples’ lives. We are grateful to her ongoing
commitment as well as for the expertise and knowledge she has
shared with us over the last decade. I know she will continue to
add significant value as a member of our Board of Directors.
Congratulations, Rosemary and thank you," said Nicholas Vita, CEO,
Columbia Care.
Dr. Mazanet began her career in Internal Medicine and Oncology
at the Brigham and Women’s Hospital and the Dana Farber Cancer
Institute before starting at Amgen in the early 1990s as the head
of Clinical Research. At Amgen, Dr. Mazanet held broad
responsibilities as one of the first U.S. trained clinician
scientists in her field, where she led multiple successful product
development initiatives, including FDA panel presentations for
groundbreaking stem-cell therapies such as Neupogen. Following her
time at Amgen, she moved into public equity in 1998 when she joined
Oracle Partners LLC in New York as a General Partner. Since that
time, she has been a presence in public and private equity biotech
and specialty pharma investments. In addition to the Columbia Care
Board of Directors, Dr. Mazanet is also an Emeritus Trustee at the
University of Pennsylvania School of Medicine and the Co-Chair of
the Leonard Davis Institute Executive Advisory Board at The Wharton
School of the University of Pennsylvania. Dr. Mazanet graduated
magna cum laude from the University of Virginia and completed her
graduate work at the University of Pennsylvania Medical School and
Harvard Medical School.
About Columbia Care
Columbia Care is one of the largest and most experienced
cultivators, manufacturers and providers of cannabis products and
related services, with licenses in 16 U.S. jurisdictions. Columbia
Care operates 125 facilities including 94 dispensaries and 31
cultivation and manufacturing facilities, including those under
development. Columbia Care is one of the original multi-state
providers of medical cannabis in the U.S. and now delivers
industry-leading products and services to both the medical and
adult-use markets. In 2021, the company launched Cannabist, its
retail brand, creating a national dispensary network that leverages
proprietary technology platforms. The company offers products
spanning flower, edibles, oils and tablets, and manufactures
popular brands including Seed & Strain, Triple Seven, Hedy,
gLeaf, Classix, Press, and Amber. For more information on Columbia
Care, please visit www.columbia.care.
Caution Concerning Forward Looking Statements
This press release contains certain statements that constitute
“forward-looking information” or “forward-looking statements”
within the meaning of applicable securities laws and reflect the
Company’s current expectations regarding future events.
Forward-looking statements or information contained in this release
include, but are not limited to, statements or information with
respect to the executive management transition. These
forward-looking statements or information, which although
considered reasonable by the Company, may prove to be incorrect and
are subject to known and unknown risks and uncertainties that may
cause actual results, performance or achievements of the Company to
be materially different from those expressed or implied by any
forward-looking information. In addition, securityholders should
review the risk factors discussed under “Risk Factors” in Columbia
Care’s Form 10-K for the year ended December 31, 2022, as, filed
with Canadian and U.S. securities regulatory authorities and
described from time to time in subsequent documents filed with
applicable securities regulatory authorities.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230911210563/en/
Investors Lee Ann Evans SVP, Capital Markets
+1.212.271.0915 ir@col-care.com
Media Lindsay Wilson SVP, Communications +1.978.662.2038
media@col-care.com
Grafico Azioni Ordinary (TG:3LP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Ordinary (TG:3LP)
Storico
Da Giu 2023 a Giu 2024